The knockdown of P2X7 receptors with the utilization of selective or specific antagonists (A-438079, A-740003, and A-839977) benefits cancer pain by reducing the release of cytokine, such as Il-1β (66, 72, 73). The gene discussed is IL1B; the disease is cancer.